Administration of irbesartan was associated with reduced kidney weight when compared with perindopril-treated animals. Similarly, rats treated with the combination of irbesartan and perindopril had ...

Pharvaris announced abstract acceptances for the 2025 National Summit on hereditary angioedema, featuring multiple poster presentations on deucrictibant.

Perindopril normalises small artery morphology, reduces left ventricular mass and improves coronary reserves. [34, 35] In a comparative study involving 30 previously untreated patients with ...

ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ...

Extension of the dosing interval of lanadelumab remains effective in preventing HAE attacks. Extending the lanadelumab dosing interval to 300 mg once every 4 weeks retains effectiveness in preventing ...

The following is a list of health product advisories, type I drug recalls and summaries of completed safety reviews published in May 2025 by Health Canada. This safety review evaluated the risk of ...

The FDA has approved Andembry, a monthly treatment for hereditary angioedema, providing a new option for patients to manage this condition effectively.

The approval of Andembry is for use in adult and pediatric patients aged 12 years and older and is self-administered with once-monthly dosing delivered in 15 seconds or less via an autoinjector ...

FRIDAY, June 20, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Andembry (garadacimab-gxii) as the only treatment targeting factor XIIa for prophylactic use to prevent ...